Ascendis Pharma A/S (ASND) Expected to Announce Earnings of -$1.18 Per Share

Brokerages expect Ascendis Pharma A/S (NASDAQ:ASND) to report ($1.18) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Ascendis Pharma A/S’s earnings, with the highest EPS estimate coming in at ($1.02) and the lowest estimate coming in at ($1.31). Ascendis Pharma A/S reported earnings of ($1.08) per share during the same quarter last year, which indicates a negative year over year growth rate of 9.3%. The business is scheduled to report its next quarterly earnings report on Wednesday, March 27th.

According to Zacks, analysts expect that Ascendis Pharma A/S will report full-year earnings of ($3.90) per share for the current fiscal year, with EPS estimates ranging from ($4.13) to ($3.28). For the next fiscal year, analysts forecast that the business will report earnings of ($3.49) per share, with EPS estimates ranging from ($5.50) to ($0.44). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Ascendis Pharma A/S.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Wednesday, November 28th. The biotechnology company reported ($0.94) earnings per share for the quarter, topping the consensus estimate of ($1.23) by $0.29. The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.16 million. Ascendis Pharma A/S had a negative return on equity of 45.44% and a negative net margin of 38,569.44%.

A number of analysts have commented on the company. BidaskClub upgraded Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research report on Thursday. ValuEngine raised Ascendis Pharma A/S from a “buy” rating to a “strong-buy” rating in a report on Wednesday, December 5th. Credit Suisse Group boosted their price target on Ascendis Pharma A/S from $80.00 to $86.00 and gave the stock an “outperform” rating in a report on Thursday, November 29th. Finally, Zacks Investment Research cut Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a report on Tuesday, November 13th. Two research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $77.56.

Shares of Ascendis Pharma A/S stock traded down $1.43 during trading on Friday, reaching $69.25. The company’s stock had a trading volume of 127,923 shares, compared to its average volume of 239,337. Ascendis Pharma A/S has a 12-month low of $45.17 and a 12-month high of $76.99. The company has a market cap of $2.94 billion, a PE ratio of -15.99 and a beta of 0.86.

Institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC increased its stake in Ascendis Pharma A/S by 750.9% in the second quarter. Renaissance Technologies LLC now owns 56,500 shares of the biotechnology company’s stock valued at $3,758,000 after purchasing an additional 49,860 shares during the last quarter. Alps Advisors Inc. increased its stake in Ascendis Pharma A/S by 22.7% during the third quarter. Alps Advisors Inc. now owns 65,448 shares of the biotechnology company’s stock worth $4,638,000 after acquiring an additional 12,124 shares during the last quarter. Alliancebernstein L.P. increased its stake in Ascendis Pharma A/S by 2.7% during the third quarter. Alliancebernstein L.P. now owns 714,366 shares of the biotechnology company’s stock worth $50,620,000 after acquiring an additional 19,039 shares during the last quarter. Fosun International Ltd acquired a new stake in Ascendis Pharma A/S during the third quarter worth about $3,544,000. Finally, FMR LLC increased its stake in Ascendis Pharma A/S by 24.3% during the third quarter. FMR LLC now owns 4,152,262 shares of the biotechnology company’s stock worth $294,230,000 after acquiring an additional 812,468 shares during the last quarter. Hedge funds and other institutional investors own 95.60% of the company’s stock.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

See Also: What is the Consumer Price Index (CPI)?

Get a free copy of the Zacks research report on Ascendis Pharma A/S (ASND)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply